Advertisement

Picture BIO Deutschland Corona Special Germany 2020 650x80px
Organisation › Details

Genmab A/S (CSE: GEN, Nasdaq: GMAB)

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base includes a number of proprietary next generation antibody technologies Genmab has alliances with other leading pharmaceutical and biotechnology companies. *

 

Period Start 1999-01-01 established
  Group Genmab (Group)
Products Industry DuoBody technology platform (bispecific antibodies)
  Industry 2 Darzalex®
Person Person van de Winkel, Jan (Genmab 201106 CEO before CSO + Co-Founder before Medarex Europe)
     
Region Region København (Copenhagen)
  Country Denmark
  Street 43 Kalvebod Brygge
  City 1560 Copenhagen V
  Tel +45-70-202728
    Address record changed: 2019-07-14
     
Basic data Employees D: 101 to 500 (2018-12-31)
  Currency DKK
  Annual sales 3,040,539,000 (revenue, consolidated (2018) 2018-12-31)
  Profit 1,472,141,000 (2018-12-31)
  Cash 478,190,000 (2018-12-31)
     
    * Document for �About Section�: Genmab A/S. (7/12/19). "Press Release: Genmab and Blink Biomedical Enter into Commercial License Agreement". Copenhagen.
     
   
Record changed: 2020-04-03

Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

More documents for Genmab (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture [iito] Made Without Love 650x80px




» top